CURRENT ISSUE
EDITOR'S PICKS
ARTICLES IN THREE SENTENCES
Article
Inotuzumab ozogamicin combined with chemotherapy in pediatric B-cell precursor CD22+ acute lymphoblastic leukemia: results of the phase IB ITCC-059 trial
Phase IB of the ITCC-059 trial tested inotuzumab ozogamicin (InO) combined with chemotherapy in pediatric CD22+ relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Preliminary efficacy and safety data reported by Pennesi and colleagues show that the combination of InO with vincristine, dexamethasone and intrathecal therapy is safe. However, the efficacy of the combination regimen was not superior to that of single-agent InO in the same trial, thus suggesting the use of less chemo-intensive treatments.
Article
The diversity of the microbiome impacts chronic lymphocytic leukemia development in mice and humans
The significance of the gut microbiome, an ecosystem formed by commensal, symbiotic, and pathogenic microorganisms colonizing the gastrointestinal tract, in both health and disease is a rapidly growing field of research. Faitová and colleagues investigated the influence of gut microbiome diversity on the development of chronic lymphocytic leukemia (CLL) in humans and mice. Their taxonomic microbiome analyses provide evidence for a link between microbiome diversity and CLL development and aggressiveness in patients with CLL and mouse models, respectively.
Article
Continuous and differential improvement in worldwide access to hematopoietic cell transplantation: activity has doubled in a decade with a notable increase in unrelated and non-identical related donors
The Worldwide Network for Blood and Marrow Transplantation (WBMT) aims at narrowing the gaps between countries in hematopoietic cell transplantation (HCT) programs by conducting workshops to promote and support existing programs and develop innovative ones. Thanks to a survey of the WBMT, Atsuta and colleagues report the worldwide developments of HCT programs up to the year 2018. The use of HCT doubled in about a decade at different speeds and with significant changes regarding donor match, and, although narrowing, significant gaps remain between developing and non-developing countries.
Letter
Universal germline genetic testing in patients with hematologic malignancies using DNA isolated from nail clippings
Nail clippings represent a non-invasive source of DNA that can be used for germline testing. Ceyhan-Birsoy and colleagues describe a novel, clinically validated, and New York State Department of Health-approved nail-DNA-based next-generation sequencing germline testing assay for patients with hematologic malignancies (HM). The study shows the feasibility of large-scale genetic testing, which will help determine which patients with HM are most likely to benefit from routine genetic testing and provide an opportunity to improve the availability and efficiency of clinical germline testing for individuals with HM in the future.
TAKE ADVANTAGE FROM HAEMATOLOGICA
